Search research articles
Contact Us
Filters
Showing results (1-10 of 71) with videos related to
Page
of 8
Sort By:
The Journal of Urology
|
February 10, 2022
Editorial Comment
Nicolas Sayegh, Umang Swami
JCO Precision Oncology
|
March 21, 2025
Histone Deacetylase Inhibitors in the Management of Advanced Cancers
Nicolas Sayegh, Valerie Etzrodt
The Lancet. Healthy Longevity
|
October 23, 2022
Benign prostatic hyperplasia: a global challenge of the ageing population
Nicolas Sayegh, Kelli Gross
JCO Oncology Practice
|
September 2, 2021
Recent Advances in the Management of Metastatic Prostate Cancer
Nicolas Sayegh, Umang Swami, Neeraj Agarwal
European Urology Oncology
|
June 21, 2021
Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations
Nicolas Sayegh, Neeraj Agarwal, Umang Swami
JACC. Cardiooncology
|
July 12, 2022
Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies
Avirup Guha, Nicolas Sayegh, Neeraj Agarwal
European Urology
|
December 13, 2021
Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer
Umang Swami, Nicolas Sayegh, Neeraj Agarwal
Cancer Cell
|
April 16, 2021
Seeing the forest for the trees-single-cell atlases link CD8<sup>+</sup> T cells and macrophages to disease progression and treatment response in kidney cancer
Mei Yee Koh, Nicolas Sayegh, Neeraj Agarwal
Cancer Treatment and Research Communications
|
January 31, 2021
Body composition and metastatic prostate cancer survivorship
Adriana M Coletta, Nicolas Sayegh, Neeraj Agarwal
Oncotargets and Therapy
|
October 3, 2022
Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
Nicolas Sayegh, Nishita Tripathi, Neeraj Agarwal, et al.
Page
of 8
Search research articles
Search
Showing results (1-10 of 71) with videos related to
Sort By:
Page
of 8
The Journal of Urology
|
February 10, 2022
Editorial Comment
Nicolas Sayegh, Umang Swami
JCO Precision Oncology
|
March 21, 2025
Histone Deacetylase Inhibitors in the Management of Advanced Cancers
Nicolas Sayegh, Valerie Etzrodt
The Lancet. Healthy Longevity
|
October 23, 2022
Benign prostatic hyperplasia: a global challenge of the ageing population
Nicolas Sayegh, Kelli Gross
JCO Oncology Practice
|
September 2, 2021
Recent Advances in the Management of Metastatic Prostate Cancer
Nicolas Sayegh, Umang Swami, Neeraj Agarwal
European Urology Oncology
|
June 21, 2021
Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations
Nicolas Sayegh, Neeraj Agarwal, Umang Swami
JACC. Cardiooncology
|
July 12, 2022
Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies
Avirup Guha, Nicolas Sayegh, Neeraj Agarwal
European Urology
|
December 13, 2021
Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer
Umang Swami, Nicolas Sayegh, Neeraj Agarwal
Cancer Cell
|
April 16, 2021
Seeing the forest for the trees-single-cell atlases link CD8<sup>+</sup> T cells and macrophages to disease progression and treatment response in kidney cancer
Mei Yee Koh, Nicolas Sayegh, Neeraj Agarwal
Cancer Treatment and Research Communications
|
January 31, 2021
Body composition and metastatic prostate cancer survivorship
Adriana M Coletta, Nicolas Sayegh, Neeraj Agarwal
Oncotargets and Therapy
|
October 3, 2022
Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
Nicolas Sayegh, Nishita Tripathi, Neeraj Agarwal, et al.
Page
of 8